Although the clinical evaluation of the efficacy of immune checkpoint inhibitors in sinonasal cancer is still in its early phases, preliminary data indicate that response to treatment may be associated not only to immune marker status (i.e., PDL1 expression, tumor infiltrating lymphocytes and tumor microenvironment subtype) but also to tumor genotypes [58]. Here, CD274 is linked to neoplasm.